Evidence map›Paper›PMID 42030010›Full record

ArticleJournal of clinical pharmacology2026

A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on Hemodialysis.

Caroline Mohrmann, Rajneet K Oberoi, Stephen D Flach, Thomas C Marbury, Pedro Hernandez, Manoj Gokhale, Celeste R MacElrevey, Caitlin Sampson, Hamid Amouzadeh, Krischan Hudson and 2 more

Erratum issuedAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Caroline MohrmannAmgen Inc., Thousand Oaks, CA, USA.ORCID 0000-0002-1198-0433
Rajneet K OberoiAmgen Inc., Thousand Oaks, CA, USA.ORCID 0000-0001-9522-9948
Stephen D FlachFortrea Inc., Durham, NC, USA.
Thomas C MarburyOrlando Clinical Research Center, Orlando, FL, USA.
Pedro HernandezFloridian Clinical Research, Miami Lakes, FL, USA.
Manoj GokhaleFortrea Inc., Durham, NC, USA.
Celeste R MacElreveyFortrea Inc., Durham, NC, USA.
Caitlin SampsonAmgen Inc., Thousand Oaks, CA, USA.
Hamid AmouzadehAmgen Inc., Thousand Oaks, CA, USA.
Krischan HudsonAmgen Inc., Thousand Oaks, CA, USA.
Vijay V UpretiAmgen Inc., South San Francisco, CA, USA.ORCID 0000-0003-1018-7166
Jessica A WardAmgen Inc., Thousand Oaks, CA, USA.

Funding

Amgen Inc.
6 · The paper itself

Abstract

The effect of end-stage kidney disease (ESKD) and hemodialysis (HD) on avacopan exposure is unknown. This Phase 1 study evaluated the pharmacokinetics (PK) and safety of avacopan and its active metabolite M1 in healthy participants and participants with ESKD requiring HD following a single 30-mg oral dose administered with food. Healthy participants (N = 6) received one dose of avacopan, while participants with ESKD (N = 7) received a single 30-mg oral dose during each treatment period 18 days apart: once 4 h before HD and once on a non-HD day. PK parameters included area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUC

Indexed as

Kidney Failure, ChronicRenal DialysisAdministration, OralAdultAgedArea Under CurveFemaleHumansMaleMiddle AgedYoung Adultavacopanend‐stage kidney diseasehemodialysispharmacokineticssafety

Identifiers

PMID42030010
PMCPMC13108541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.